Genomic Valley Biotech standalone net profit rises 333.33% in the June 2024 quarter

Genomic Valley Biotech reports standalone net profit of Rs 0.06 crore in the September 2022 quarter

Genomic Valley Biotech reports standalone net profit of Rs 0.01 crore in the December 2021 quarter

Genomic Valley Biotech reports standalone net loss of Rs 0.11 crore in the June 2021 quarter

Genomic Valley Biotech reports standalone net loss of Rs 0.38 crore in the March 2021 quarter

Genomic Valley Biotech reports standalone net loss of Rs 0.01 crore in the December 2020 quarter

Price return has been average, nothing exciting

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Average profitability - not good, not bad

Profitability

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

The stock has a moderate number of red flags

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Genomic Valley Biotech Ltd is conducting research in the field of Biotechnology (Plant & Animal) and also to undertake commercial production of Plant Tissue Cultured Plants of different species to feed the genetically improved plant market